Cloud Banner

Pharmaceutical

Image

Global Muscular Dystrophy Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Muscular Dystrophy Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR - 42.2% Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 2.13 Billion
Diagram Market Size (Forecast Year) USD 35.61 Billion
Diagram CAGR 42.2%

Global Muscular Dystrophy Drugs Market, By Drugs Corticosteroids, Eteplirsen, Golodirsen, Cardiovascular Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Muscular Dystrophy Drugs Market

Muscular Dystrophy Drugs Market Analysis and Size

The diagnosed widespread cases of muscular dystrophy are estimated to increase in the U.S. and decrease in Japan between 2020 to 2030. In 2020, deletion mutation was the most predominant mutation among this disorder cases. The least prevalent mutation type was the splice site mutation. The U.S. represents more than 90% of the DMD sales in 2020, but its contribution is projected to decline in 2030. Steroids can treat all muscular dystrophy patient, regardless of mutation types.

Data Bridge Market Research analyses a growth rate in the global muscular dystrophy drugs market in the forecast period 2022-2029. The expected CAGR of global muscular dystrophy drugs market is tend to be around 42.2% in the mentioned forecast period. The market was valued at USD 2.13 billion in 2021, and it would grow upto USD 35.61 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Muscular Dystrophy Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drugs (Corticosteroids, Eteplirsen, Golodirsen, Cardiovascular Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Boehringer Ingelheim International Gmbh (Germany), Sanofi (France), Sarepta Therapeutics, Inc (U.K.), FibroGen, Inc. (U.S.)

Market Opportunities

  • Rising R&D and New Drug Approvals
  • Varied New Treatments

Market Definition

Muscular dystrophy is a group of diseases wherein loss of muscle mass or muscle weakness occurs. In muscular dystrophy, which is a gene mutation occurs that interferes with the protein production needed for the healthy muscles. As there is no prominent cure for muscular dystrophy, medication and other therapy may decrease the symptoms. Patients suffering from this disorder have symptoms such as frequent falls, troubling in walking, jumping and running, large calf muscle among others.

Global Muscular Dystrophy Drugs Market Dynamics

Drivers

  • Increased Use of Corticosteroids

Compared to the several other products, corticosteroids are possibly to evolve as the top-selling products during 2022-2029. By 2029 end, corticosteroids are anticipated to cross US$ 9,000 million revenue. Several scientific research has found that compared to several products to treat muscular dystrophy, corticosteroids helps in improving the muscle strength for up to 2-5 years. However, the long-term benefit of corticosteroids is yet a vague concept.

  • Increasing Clinical Research

Currently, numerous clinical trials are being conducted to evaluate potential treatments for muscular dystrophy. The only approved pharmacological therapy for managing this condition is an anti-inflammatory regimen that is based on corticosteroids. In the recent times, there has been a huge rise in the discovery and development of pharmaceutical drugs. Around all major companies are now focusing on R&D, possibly leaving a major impact on the market in the upcoming years.

Opportunities

  • Varied New Treatments

Among the numerous treatment types, exon-skipping is holding a great demand. Internal deletions in the gene for dystrophin are the major cause of muscular dystrophy. To allow the remaining exons to come altogether, one therapeutic strategy is to mask an exon near the location where the other exons are missing. For instance, in June 2022, Novartis announced, that the European Commission (EC) approved Tabrecta as a monotherapy for the treatment of adults suffering from advanced non-small cell lung cancer (NSCLC) which has mutations that cause exon 14 skipping and who require systemic therapy after receiving prior immunotherapy or platinum-based chemotherapy.

  • Rising R&D and New Drug Approvals

The unmet needs of patients suffering from myelofibrosis are encouraging manufacturers to develop new solutions. The increasing investments in the R&D activities to develop a precise treatment for myelofibrosis is projected to boost the growth of the industry in the forecast period. The quick technological advancements and ongoing clinical trials contribute to industry growth. Other factors such as reimbursement policies, favourable government initiatives, improved healthcare sector, busy lifestyle and changing dietary patterns are also contributing to the industry growth.   

 Restraints/Challenges

  • Lack of Awareness

The lack of awareness about muscular dystrophy and the unavailability of numerous awareness programs hamper the market growth.

  • Insufficient Funds

The insufficient funds that are associated with the treatment processes are hampering the growth of the market. Several private and government organizations are withdrawing their funds or not providing enough funds for the high-end treatment processes impeding the market's growth.

This global muscular dystrophy drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global muscular dystrophy drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Muscular Dystrophy Drugs Market Scope

The global muscular dystrophy drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Corticosteroids
  • Eteplirsen
  • Golodirsen
  • Cardiovascular Medication
  • Others

Route of Administration

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

 Muscular Dystrophy Drugs Market Regional Analysis/Insights

The global muscular dystrophy drugs market is analyzed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global muscular dystrophy drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for global muscular dystrophy drugs market throughout the forecast period because of the increased awareness about the diseases and rapidly disposable income.

North America dominates the market because of the increase prevalence of myelofibrosis (MF), high demand of targeted therapies and advanced healthcare facilities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Muscular Dystrophy Drugs Market Share Analysis

The global muscular dystrophy drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global muscular dystrophy drugs market.

Key players operating in the global muscular dystrophy drugs market include:

  • Pfizer Inc (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Mylan N.V. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Hikma Pharmaceuticals PLC (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol Myers Squibb Company (U.S.)
  • GSK Plc. (U.K.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd (India)
  • Boehringer Ingelheim International Gmbh (Germany)
  • Sanofi (France)
  • Sarepta Therapeutics, Inc (U.K.)
  • FibroGen, Inc. (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Muscular Dystrophy Drugs Market is projected to grow at a CAGR of 42.2% during the forecast period by 2029.
The future market value of the Muscular Dystrophy Drugs Market is expected to reach USD 35.61 billion by 2029.
The major players in the Muscular Dystrophy Drugs Market are Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.), etc.
The countries covered in the Muscular Dystrophy Drugs Market are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, etc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials